```
d his

     (FILE 'HOME' ENTERED AT 09:00:56 ON 02 SEP 2005)

     FILE 'DISSABS, 1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX,
     COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, OCEAN,
     PAPERCHEM2, PASCAL, POLLUAB, SOLIDSTATE, ADISCTI, ADISINSIGHT, ADISNEWS,
     ANABSTR, ANTE, AQUALINE, BIOBUSINESS, BIOCOMMERCE, ' ENTERED AT 09:01:07
     ON 02 SEP 2005
L1          1690 S NOPE
L2           122 S L1 AND (VENTRICULAR ZONE OR DCC OR PUNC OR NCAM OR AXONAL OR
L3            68 S  L2 AND (FUNCTION OR ACTIVITY)
L4            67 DUP REM L3 (1 DUPLICATE REMOVED)

=>
```

L4 ANSWER 19 OF 67 DGENE COPYRIGHT 2005 The Thomson Corp on STN
ACCESSION NUMBER: AAU77405 Protein DGENE
TITLE: Novel cytoplasmic, nuclear, membrane bound and secreted NOVX polypeptides, useful for treating developmental disorders, endocrine disorders, vascular disorders, infectious diseases and neurodegenerative disorders -
INVENTOR: Rastelli L; Shimkets R A; Zerhusen B; Malyankar U M; Padigaru M
PATENT ASSIGNEE: (CURA-N)CURAGEN CORP.
PATENT INFO: WO 2002006329 A2 20020124 178
APPLICATION INFO: WO 2001-US22709 20010718
PRIORITY INFO: US 2000-218870P 20000718
US 2000-218875P 20000718
US 2000-218901P 20000718
US 2000-220273P 20000724
US 2000-220912P 20000726
US 2000-221233P 20000727
US 2000-221650P 20000728
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-179781 [23]
CROSS REFERENCES: N-PSDB: ABK11101
DESCRIPTION: Human NOV1 protein, homologue of **NOPE/PUNC** Ig proteins.
AB The present invention relates to the isolation of novel human polypeptides referred to as NOV1, NOV2, NOV3, NOV4a, NOV4b, NOV5A, NOV5b, NOV6 AND NOV7, and the polynucleotide sequences encoding them. The NOVX polypeptides are related to **NOPE**, cadherin, interferon alpha-13, ADAM, ankyrin repeat-containing, transpanin or semaphorin polypeptides. The sequences of the invention are useful for identifying an agent (a cellular receptor or downstream effector) that binds to the NOVX polypeptide, or an agent that modulates it's expression or **activity**. They are useful for treating or preventing NOVX-associated disorders such as developmental disorders, endocrine disorders, vascular diseases, gastrointestinal disorders, respiratory disorders, inflammatory disorders, blood disorders, reproductive disorders, neurodegenerative disorders, autoimmune and immune disorders, infectious diseases, cardiovascular disorders, cancers, and other disorders related to cell signal processing and metabolic pathway modulation. The present sequence represents the human NOV1 protein.
DESC Human NOV1 protein, homologue of **NOPE/PUNC** Ig

L4 ANSWER 31 OF 67 DGENE COPYRIGHT 2005 The Thomson Corp on STN
ACCESSION NUMBER: AAE05252 Protein DGENE
TITLE: Murine **Nope** polypeptides and nucleic acids useful for preventing, diagnosing and treating colonic cancer and Bardet-Biedl syndrome -
INVENTOR: Salbaum J M
PATENT ASSIGNEE: (NEUR-N)NEUROSCIENCES RES FOUND INC.
PATENT INFO: WO 2001049714 A2 20010712 99
APPLICATION INFO: WO 2000-US29698 20001026
PRIORITY INFO: US 2000-174496 20000104
US 2000-205789 20000519
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-441846 [47]
CROSS REFERENCES: N-PSDB: AAD10022
DESCRIPTION: Mouse **Nope** (neighbour of **punc** ell) extracellular domain.

AB The present invention relates to **Nope** (neighbour of **punc** ell) which is used in the prevention, treatment and diagnosis of diseases associated with inappropriate **Nope** expression such as cancers especially colonic cancer and genetic disorders, as **Nope** is thought to be a tumour suppressor. **Nope** gene is located on chromosome 9 and is used in gene therapy. **Nope** is used as vaccine. **Nope** gene may be administered to treat diseases by rectifying mutations or deletions in a patient's genome that affect the **activity** of **Nope** by expressing inactive proteins or to supplement the patients own production of **Nope** polypeptides. **Nope** gene is used to study the expression and **function** of **Nope** polypeptides and their role in metabolism through the creation of transgenic animal models. The anti-**Nope** antibodies and **Nope** antagonists may also be used to down regulate **Nope** expression and **activity** for the treatment of Bardet-Biedl syndrome which is an autosomal recessive disorder characterised by mental retardation, obesity, polydactyly, retinitis pigmentosa and hypogonadism. Patients with Bardet-Biedl syndrome have a high incidence of hypertension, diabetes mellitus and renal and cardiovascular anomalies. The present sequence is mouse **Nope** (neighbour of **punc** ell) extracellular domain.

TI Murine **Nope** polypeptides and nucleic acids useful for preventing, diagnosing and treating colonic cancer and Bardet-Biedl syndrome -

DESC Mouse **Nope** (neighbour of **punc** ell) extracellular domain.

KW Mouse; **Nope**; neighbour of **punc** ell; cytostatic; neuroprotective; vaccine; gene therapy; cerebroprotective; colonic cancer; mental retardation; tumour suppressor; chromosome 9; transgenic animal; genetic disorder; obesity;. . .

AB The present invention relates to **Nope** (neighbour of **punc** ell) which is used in the prevention, treatment and diagnosis of diseases associated with inappropriate **Nope** expression such as cancers especially colonic cancer and genetic disorders, as **Nope** is thought to be a tumour suppressor. **Nope** gene is located on chromosome 9 and is used in gene therapy. **Nope** is used as vaccine. **Nope** gene may be administered to treat diseases by rectifying mutations or deletions in a patient's genome that affect the **activity** of **Nope** by expressing inactive proteins or to supplement the patients own production of **Nope** polypeptides. **Nope** gene is used to study the expression and **function** of **Nope** polypeptides and their role in metabolism through the creation of transgenic animal models. The anti-**Nope** antibodies and **Nope** antagonists may also be used to down regulate **Nope** expression and **activity** for the treatment of Bardet-Biedl syndrome which is an autosomal recessive disorder characterised by mental retardation, obesity, polydactyly, retinitis pigmentosa. . . Bardet-Biedl syndrome have a high incidence of hypertension, diabetes mellitus and renal and cardiovascular anomalies. The present sequence is mouse **Nope**

(neighbour of punc ell) extracellular domain.

L4 ANSWER 32 OF 67 DGENE COPYRIGHT 2005 The Thomson Corp on STN
ACCESSION NUMBER: AAE05251 Protein DGENE
TITLE: Murine **Nope** polypeptides and nucleic acids useful for preventing, diagnosing and treating colonic cancer and Bardet-Biedl syndrome -
INVENTOR: Salbaum J M
PATENT ASSIGNEE: (NEUR-N)NEUROSCIENCES RES FOUND INC.
PATENT INFO: WO 2001049714 A2 20010712 99
APPLICATION INFO: WO 2000-US29698 20001026
PRIORITY INFO: US 2000-174496 20000104
US 2000-205789 20000519
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-441846 [47]
CROSS REFERENCES: N-PSDB: AAD10021
DESCRIPTION: Mouse **Nope** (neighbour of **punc** ell) protein.

AB The present invention relates to **Nope** (neighbour of **punc** ell) which is used in the prevention, treatment and diagnosis of diseases associated with inappropriate **Nope** expression such as cancers especially colonic cancer and genetic disorders, as **Nope** is thought to be a tumour suppressor. **Nope** gene is located on chromosome 9 and is used in gene therapy. **Nope** is used as vaccine. **Nope** gene may be administered to treat diseases by rectifying mutations or deletions in a patient's genome that affect the **activity** of **Nope** by expressing inactive proteins or to supplement the patients own production of **Nope** polypeptides. **Nope** gene is used to study the expression and **function** of **Nope** polypeptides and their role in metabolism through the creation of transgenic animal models. The anti-**Nope** antibodies and **Nope** antagonists may also be used to down regulate **Nope** expression and **activity** for the treatment of Bardet-Biedl syndrome which is an autosomal recessive disorder characterised by mental retardation, obesity, polydactyly, retinitis pigmentosa and hypogonadism. Patients with Bardet-Biedl syndrome have a high incidence of hypertension, diabetes mellitus and renal and cardiovascular anomalies. The present sequence is mouse **Nope** (neighbour of **punc** ell) protein.

TI Murine **Nope** polypeptides and nucleic acids useful for preventing, diagnosing and treating colonic cancer and Bardet-Biedl syndrome -

DESC Mouse **Nope** (neighbour of **punc** ell) protein.

KW Mouse; **Nope**; neighbour of **punc** ell; cytostatic; neuroprotective; vaccine; gene therapy; cerebroprotective; colonic cancer; mental retardation; tumour suppressor; chromosome 9; transgenic animal; genetic disorder; obesity;. . .

AB The present invention relates to **Nope** (neighbour of **punc** ell) which is used in the prevention, treatment and diagnosis of diseases associated with inappropriate **Nope** expression such as cancers especially colonic cancer and genetic disorders, as **Nope** is thought to be a tumour suppressor. **Nope** gene is located on chromosome 9 and is used in gene therapy. **Nope** is used as vaccine. **Nope** gene may be administered to treat diseases by rectifying mutations or deletions in a patient's genome that affect the **activity** of **Nope** by expressing inactive proteins or to supplement the patients own production of **Nope** polypeptides. **Nope** gene is used to study the expression and **function** of **Nope** polypeptides and their role in metabolism through the creation of transgenic animal models. The anti-**Nope** antibodies and **Nope** antagonists may also be used to down regulate **Nope** expression and **activity** for the treatment of Bardet-Biedl syndrome which is an autosomal recessive disorder characterised by mental retardation, obesity, polydactyly, retinitis pigmentosa. . . Bardet-Biedl syndrome have a high incidence of hypertension, diabetes mellitus and renal and cardiovascular anomalies. The present sequence is mouse **Nope**